Higher objective response rates to PDCD1/CD274 monotherapy have been associated with a number of factors, including immunogenicity of the tumor [8], male sex, age < 65 years, current and former smokers, a lack of central nervous system or liver metastasis, and a lack of EGFR mutations [7]. This evidence concerns the gene CD274 and neoplasm.